Nivolumab after chemoradiation for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests nivolumab (an immune system–boosting antibody) given after standard chemoradiation to help keep advanced nasopharyngeal cancer from coming back or progressing. It may help your immune system better find and attack cancer cells after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 19 years or older, and have confirmed advanced nasopharyngeal cancer (stage II to IVa).
- Have completed standard chemoradiation and your treatment side effects are mostly gone (no worse than grade 1).
- Be able to do most daily activities (ECOG performance status 0 or 1).
- Have basic blood and organ test results within set limits, done within 7 days of starting the study drug.
- If you’ve had growth-factor shots (G-CSF) or a blood transfusion in the last 14 days, your recent lab tests may not count—repeat testing may be needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immune-based drugs (sintilimab and bevacizumab) plus standard chemotherapy for people with high-risk, locally advanced nasopharyngeal cancer that has spread to lymph nodes. The goal is to see if this approach works better than current treatments.
This trial tests a new immunotherapy drug (serplulimab) given together with standard chemotherapy and radiation for nasopharyngeal cancer that has spread to nearby lymph nodes. It aims to see if adding this drug can help shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy (GP), nimotuzumab, and sintilimab before standard treatment for locally advanced nasopharyngeal cancer. It aims to see if this approach can improve outcomes.
This trial studies whether adding envafolimab (an immune medicine) to standard chemo and radiation works better for people with locally advanced, untreated nasopharyngeal cancer. It may help the immune system attack the cancer while treatment shrinks it.
This trial studies nivolumab (an immune therapy) for nasopharyngeal cancer that grew or returned after platinum chemotherapy. It aims to shrink tumors or slow cancer growth after standard treatment hasn’t worked.
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
Hear when a new Locally Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.